Impacto do tratamento na expressão de S100A8/A9 na saliva de pacientes com doença peri-implantar

Abstract

We aimed to evaluate the impact of treatment on S100A8 / A9 heterodimer expression in patients with peri-implant mucositis and peri-implantitis. Forty-seven patients were evaluated and divided into two groups: (1) Peri-implant mucositis, with a mean age (MI) of 63.1 years (Standard Deviation [SD] ± 7.7) and (2) Peri-implantitis with MI 61.2 (SD ± 7.0). The clinical parameters evaluated were: pocket depth (PD), clinical attachment level (CAL), percentage of visible plaque (%plaque), and percentage of bleeding on probing (%bleeding). Unstimulated whole saliva was collected at baseline (T0) and three months after treatment (T1). Peri-implant mucositis was treated with supra-gingival scaling and prophylaxis. Peri-implantitis was treated with open flap debridement. S100A8 / A9 levels were measured by ELISA. Our results showed that, in the mucositis group, there was a significant reduction in PD (p=0.001),% plaque (p=0.005) and % bleeding (p <0.001) after treatment. In the peri-implantitis group, there was a significant reduction in PD (p <0.001) and % bleeding (p=0.001) after treatment. Regrading only the Peri-implant parameters, the mucositis group showed a reduction in PD (p <0.001), CAL (p <0.001), %plaque (p=0.022) and %bleeding (p<0.001). In Peri-implantitis group, there was also a significant reduction in PD (p=0.02), %plaque (p=0.017), and % bleeding (p=0.002). S100A8/A9 expression reduced significantly after treatment both in peri-implant mucositis (p=0.004) and peri-implantitis (p=0.010). Therefore, we concluded that the treatment was effective to improve the clinical parameters and to reduce significantly the expression of S100A8 / A9 in patients having peri-implant diseases